How Do EMG, Nerve Studies and Genetic Tests Pin Down a Neuromuscular Disease Diagnosis?

The first sign is often small and oddly specific. A jar lid that will not turn. A foot that catches on the top stair. A calf that cramps at night for no reason anyone can name. By the time a neurologist is involved, most people have already been told a dozen reassuring things by well-meaning friends, and none of them have stuck.

What follows can feel like alphabet soup: NCS, EMG, CK, panel, exome. The logic behind it is simpler than the acronyms suggest. Every test in the work-up for EMG and genetic testing neuromuscular disease is asking one of two questions. Where along the pathway from spinal cord to muscle fiber is the signal failing? And what, at the level of a single gene, is causing that failure?

This explainer walks through both questions in the order a clinic usually asks them, what each test can and cannot say, and what the weeks in between tend to look like.

What counts as a neuromuscular disease, and why do EMG and genetic testing sit at the center of the work-up?

A neuromuscular disease is any condition that damages the chain of tissue that turns intention into movement: the motor nerve cells in the spinal cord, the peripheral nerves that run out to the limbs, the junction where nerve meets muscle, and the muscle fibers themselves. Break any link and the result looks similar from the outside, which is precisely the problem. Weakness is weakness. A dropped foot does not announce whether the fault lies in a nerve root, a long nerve in the leg or the muscle at the front of the shin.

That is why the diagnostic pathway leans so heavily on two very different tools. Electrodiagnostic testing, meaning nerve conduction studies and electromyography (EMG), is a physiology test. It measures electrical behavior in real time and answers the question of location: nerve, junction or muscle, and roughly how severe. Genetic testing is a chemistry test on a blood or saliva sample. It reads the DNA code and answers the question of cause, at least for the large group of neuromuscular conditions that are inherited.

Neither replaces the other. A nerve study can show a classic pattern of muscle disease without saying which of dozens of muscular dystrophies is responsible. A genetic panel can list a variant without saying whether that variant is actually producing the weakness in the room. The MedlinePlus overview of these studies describes them as tests that help a clinician find the site and type of nerve or muscle damage, not as tests that deliver a name on their own.

Everything else in the work-up, from the neurological examination to blood enzymes to MRI, exists to make those two central tests more accurate and, sometimes, to make one of them unnecessary.

How does a nerve conduction study actually work?

A nerve conduction study, often shortened to NCS, measures how quickly and how strongly an electrical signal travels along a peripheral nerve. Small flat electrodes are taped to the skin over a muscle or a sensory nerve. A stimulator delivers a brief pulse further up the limb. The recording electrode picks up the response, and a computer plots two things: how long the signal took to arrive, and how large the response was.

Speed and size tell different stories. Peripheral nerves are wrapped in myelin, a fatty insulating sheath that lets signals jump along at speeds a healthy adult would measure in tens of meters per second. When myelin is damaged, as in certain inherited and inflammatory neuropathies, conduction slows. When the nerve fibers themselves, the axons, are lost, the speed may stay near normal but the response shrinks because fewer fibers are answering.

The pulse itself feels like a sharp static shock or a quick tap. Mayo Clinic describes the sensation as a brief tingling or twinge; it is over in a fraction of a second, repeated several times at different sites. The test is done on both sides when possible, because comparing a symptomatic limb with a healthy one is one of the most reliable ways to spot an abnormality.

A separate technique, repetitive nerve stimulation, delivers a train of pulses in quick succession and watches whether the muscle response fades. That fading pattern points toward a problem at the neuromuscular junction, the tiny gap where nerve chemically talks to muscle, rather than in the nerve or muscle proper.

Before the appointment, most laboratories ask patients to skip lotions and keep the skin clean, because oils interfere with the electrodes, and to keep the limb warm. Cold nerves conduct slowly, and a chilly waiting room can create a false abnormality that a good technologist will recognize and correct by warming the arm or leg.

What does an EMG show that a nerve study cannot?

Electromyography records electrical activity inside a muscle. A fine needle electrode, thinner than most used for blood draws, is inserted through the skin into the muscle belly. There is no electrical stimulus in this part of the test; the needle simply listens.

Healthy muscle at rest is electrically silent. When a person gently contracts it, individual motor units fire. A motor unit is one nerve cell in the spinal cord plus every muscle fiber it controls, which may be a handful in the eye or many hundreds in the thigh. Each unit produces a characteristic waveform, and the neurologist watches those shapes on a screen and hears them through a speaker as crackles and pops.

Disease changes the sound. When a nerve has been cut off from muscle fibers, those orphaned fibers begin to twitch on their own at rest, producing tiny spontaneous discharges that should not be there. Surviving nerves send sprouts to adopt the abandoned fibers, so the remaining motor units grow larger and taller than normal. That pattern points toward a nerve or motor neuron problem.

Muscle disease looks like the mirror image. Each motor unit has lost fibers, so the waveforms become short, small and jagged, and the muscle has to recruit many units at once to produce even a weak contraction. Some muscle disorders also generate distinctive high-frequency discharges that an experienced examiner recognizes immediately.

So the answer to what an EMG shows is: which tissue is failing, how active the process is, and how it is distributed. Is it one nerve, several nerves in a stocking-and-glove pattern, a single nerve root from the spine, or muscles closest to the trunk on both sides? Johns Hopkins describes this as distinguishing between muscle disorders and nerve disorders, and that distinction shapes every step that follows, including whether genetic testing should look at nerve genes or muscle genes.

Nerve conduction study vs EMG: why are they almost always done together?

People often arrive expecting one test and are surprised to get two. The pairing is deliberate. Nerve conduction studies are excellent at evaluating the large, fast fibers of peripheral nerves and the junction, but they say little about muscle tissue itself and cannot reach nerves buried deep near the spine. Needle EMG can sample those deep muscles, including the ones along the spine that are supplied directly by nerve roots, and it is the only routine bedside way to see the electrical fingerprint of muscle disease.

Consider two people with a weak, floppy foot. In the first, the nerve study shows slowed conduction across the outside of the knee, exactly where a nerve can be compressed by prolonged leg-crossing, and the needle examination confirms that only muscles supplied by that one nerve are affected. That is a focal compression, not a neuromuscular disease in the inherited sense, and genetic testing would be the wrong next step. In the second, the nerve study is normal but the needle EMG finds small, jagged motor units in the shin muscle, in the thigh and in the shoulder. That pattern says muscle, spread widely, and it moves genetic testing for a muscular dystrophy or myopathy to the top of the list.

Timing matters too. After an acute nerve injury, the spontaneous discharges that EMG relies on take a few weeks to appear, so a study done too early can look deceptively normal. Neurologists sometimes schedule the electrodiagnostic study for a specific window for exactly this reason, and a request to wait is not a sign that concerns are being dismissed.

According to MedlinePlus, the combined study usually takes between 30 and 60 minutes, though a complex work-up sampling many muscles can run longer. Results are interpreted by the physician performing the study, who writes a report for the referring neurologist rather than delivering a final diagnosis in the room.

Who is usually referred for EMG and genetic testing for neuromuscular disease, and who is asked to wait?

The referral usually starts with a pattern rather than a single symptom. A neurologist who finds progressive weakness on examination, muscle wasting, absent reflexes, an unusual walk, or a family history of similar problems will typically order electrodiagnostic testing first. It is inexpensive in terms of risk, quick, and it steers everything afterwards.

Genetic testing tends to follow when the electrical picture, the examination and blood work together point toward an inherited cause. Typical triggers include a childhood onset of weakness, a known relative with a named condition, a distinctive distribution such as weakness that favors the shoulders and hips, a very high level of the muscle enzyme creatine kinase, or an EMG showing muscle disease without any sign of inflammation. Charcot-Marie-Tooth disease, which MedlinePlus describes as one of the most common inherited neurological disorders, is a frequent reason for testing nerve genes; Duchenne muscular dystrophy, which the NHS notes is the most common type diagnosed in children, is a frequent reason for testing muscle genes.

Who is asked to wait? Several groups, for good reasons. Someone with symptoms of only a few weeks may be asked to return for EMG once the changes have had time to develop. A person whose story and examination clearly fit a common, acquired cause such as a compressed nerve, diabetic neuropathy or an inflammatory muscle disease is usually treated for that first, because genetic testing would add little. Pregnant patients can safely have nerve studies, but non-urgent genetic panels are sometimes deferred so that counseling can happen without time pressure.

Children are a special case. Nerve studies and EMG are performed in pediatric practice, but the needle portion is uncomfortable, and many pediatric neurologists now move directly to genetic testing when the examination and enzyme results strongly suggest a specific inherited muscle disease. The order of tests is a clinical judgment, and it belongs to the treating team.

Where do blood tests, CK levels and MRI fit before genetic testing?

Between the neurological examination and the specialized tests sits a layer of ordinary blood work that does more than people expect. The most important single result is creatine kinase, usually written CK. Creatine kinase is an enzyme that lives inside muscle fibers; when fibers break down, it leaks into the bloodstream. A markedly raised CK points strongly toward muscle disease rather than nerve disease, and the NHS lists it as one of the first tests used when muscular dystrophy is suspected.

The number has to be read in context. Vigorous exercise, a recent fall, a needle EMG done a day earlier and even some prescription medicines can push CK up temporarily, so a single mildly high value rarely means much. A very high value in a young child who has never had a strenuous week, on the other hand, changes the conversation quickly.

Other blood tests rule out treatable mimics. Thyroid function, vitamin B12, blood sugar, kidney function and inflammatory markers can each explain weakness or neuropathy on their own. Certain antibody tests look for autoimmune attacks on the neuromuscular junction or on nerve proteins. Finding one of these is, in a sense, good news for the diagnostic pathway, because it points toward an acquired condition where genetic testing is not the priority.

Imaging plays a supporting role. Muscle MRI can show which muscles are replaced by fat or swollen with inflammation, and the pattern of involvement is sometimes so characteristic of a particular dystrophy that it narrows the genetic search before a sample is even sent. Spine MRI is ordered when the EMG suggests nerve root involvement, to look for a structural cause that has nothing to do with genes.

None of these tests diagnoses a neuromuscular disease alone. Their job is to build the case that justifies, or rules out, the more definitive steps that follow.

How does genetic testing pin down the exact cause?

Genetic testing reads the DNA sequence of one or more genes and compares it with a reference. Most neuromuscular genes carry instructions for a structural protein in nerve or muscle, or for an enzyme that keeps those tissues running. A change in the code, called a variant, may alter the protein enough to cause disease. MedlinePlus explains that genetic tests look for these changes in genes, chromosomes or proteins, and that the result is used to confirm or rule out a suspected condition.

The sample is nearly always blood, occasionally saliva or a cheek swab. What differs is how much of the genome the laboratory reads. A single-gene test targets one suspect when the clinical picture is unmistakable. A gene panel reads dozens to hundreds of genes known to cause a category of disease, such as hereditary neuropathies or limb-girdle muscular dystrophies. Whole exome sequencing reads the protein-coding portion of essentially every gene, and whole genome sequencing reads everything, including the regulatory regions in between.

Some conditions hide from ordinary sequencing. Several common neuromuscular diseases are caused not by a spelling change but by a stretch of repeated code that has expanded beyond a safe length, or by a whole chunk of a gene being deleted or duplicated. Standard sequencing can miss these, which is why laboratories run separate repeat-expansion or deletion-duplication analyses when the clinical suspicion calls for them. This is one reason the electrodiagnostic result matters so much: it tells the laboratory which kind of search to run.

Results come back in categories. Pathogenic and likely pathogenic variants are considered disease-causing. Benign variants are normal human variation. In between sits the variant of uncertain significance, a change the laboratory cannot yet classify. Understanding that middle category is essential, and it is where genetic counseling earns its place in the pathway.

Genetic testing for muscular dystrophy: what it can and cannot tell you

Muscular dystrophy is not one disease but a family of inherited conditions in which muscle fibers progressively weaken and break down. MedlinePlus lists more than thirty types, differing in which muscles they affect, when symptoms start and how they are passed through a family. The NHS describes genetic testing as the way to confirm a suspected type once CK and examination have raised the question.

What the test can do is name the type with precision. Duchenne and Becker muscular dystrophy both arise from changes in the same very large gene, but the nature of the change predicts which of the two is present. Facioscapulohumeral dystrophy, myotonic dystrophy and most limb-girdle dystrophies each have their own signature findings. That naming matters because it tells the care team which organs to monitor, particularly the heart and breathing muscles, and it tells relatives what their own risk might be.

What the test cannot do is predict an individual course. Two people with the same variant can differ in age at onset and rate of progression, because other genes, activity, nutrition and chance all play a part. A result is a starting point for planning, not a timetable.

The test also cannot always give a clean answer. Some people with a convincing clinical picture of muscular dystrophy receive a negative panel, either because their variant lies in a gene not yet linked to disease or in a region the test did not read. In that situation, neurologists may reanalyze the data later as knowledge grows, broaden to exome or genome sequencing, or turn to a muscle biopsy to look at the protein directly under the microscope.

Finally, a positive result in a child raises questions about siblings and parents. Carrier testing and prenatal options exist, and these conversations are best held with a genetic counselor rather than read from a report.

Which test answers which question? A side-by-side view

Patients frequently ask why they need all of these when a single test could surely settle it. The honest answer is that each tool is designed for a different question, and the table below lays out the division of labor.

Test	What it measures	Main question it answers	Key limits
Nerve conduction study	Speed and size of signals along peripheral nerves	Is a nerve damaged, and is the myelin or the axon affected?	Cannot examine muscle tissue or deep nerve roots directly
Needle EMG	Electrical activity inside muscle at rest and during contraction	Is the problem in nerve or in muscle, and how widespread is it?	Can be normal in the first weeks after nerve injury; needle discomfort
Repetitive nerve stimulation	Whether muscle response fades with rapid pulses	Is the neuromuscular junction failing?	Sensitivity depends on which muscles are tested
Creatine kinase (CK) blood test	Leakage of a muscle enzyme into blood	Is muscle breaking down?	Raised by exercise, injury and some medicines
Muscle MRI	Fat replacement, swelling and pattern of affected muscles	Which muscles are involved, and does the pattern suggest a type?	Does not name a cause on its own
Genetic panel or exome	DNA sequence of selected or all genes	Which inherited change is responsible?	Uncertain variants; may miss repeat expansions without a targeted test
Muscle biopsy	Fiber structure and protein staining under a microscope	What does the tissue itself look like when genetics is unclear?	Minor surgical procedure; result depends on which muscle is sampled

Read across the rows and a rhythm appears. The tests on the top half locate and characterize the problem. The tests on the bottom half identify its cause. A neurologist moves down the table only as far as needed, and stops when the answer is clear enough to guide care.

What do the following days and weeks usually look like?

The electrodiagnostic appointment itself is short. Mayo Clinic notes that people can typically return to normal activities immediately afterwards; there is no sedation and no recovery period. Some muscles ache for a day or two where the needle was placed, and a small bruise is possible, particularly for anyone taking a blood thinner. Warm compresses and ordinary movement are usually all that is needed, and the treating team will say if anything more is appropriate.

The report is often available to the referring neurologist within days, because the physician performing the study interprets it in real time. Whether patients hear the findings the same day varies. Many electromyographers will describe the general pattern, such as nerve or muscle involvement, but leave the final diagnosis to the follow-up visit, where it can be placed alongside everything else.

Genetic testing runs on a slower clock. MedlinePlus explains that results can take anywhere from a few days to several weeks depending on the type of test, and broader analyses such as exome sequencing commonly sit at the longer end. That interval is one of the hardest parts of the whole pathway, because nothing visible is happening and the questions keep circling. Writing them down for the results appointment is a practical use of the time.

Results are best delivered in person or by a scheduled call with a genetic counselor or neurologist, not read alone from a portal. A positive result usually leads to a plan for monitoring specific organs and a discussion about testing relatives. A negative or uncertain result leads to a decision about whether to widen the search, wait for reanalysis, or proceed to biopsy.

Across the whole process, from first referral to a settled diagnosis, months are more typical than weeks for complex cases. That pace reflects the care being taken, not a lack of it.

What are the risks, and what are the alternatives to needle EMG or genetic testing?

Both nerve studies and EMG are low-risk procedures. The electrical pulses are mild and cannot damage nerves. Johns Hopkins lists the main concerns as minor bleeding, bruising and soreness at needle sites, and a small risk of infection that is rare with sterile single-use needles. People with bleeding disorders, those on anticoagulant medicines and those with implanted electrical devices such as pacemakers should tell the laboratory in advance so the examiner can adjust technique; the study is usually still possible.

Discomfort is real but brief. Most people describe the needle portion as similar to a series of quick pinches, more noticeable in thin muscles of the hand and foot than in large thigh muscles. Telling the examiner about pain is not a nuisance; it changes how many muscles are sampled and which ones.

Genetic testing carries no physical risk beyond a blood draw. Its risks are informational. A result can reveal a condition in a relative who did not ask to know, it can generate anxiety when a variant is uncertain, and in some countries questions about insurance and employment arise. Genetic counseling before the sample is drawn exists to address exactly these concerns, and a person can reasonably decline testing after that conversation.

Alternatives exist for both tests. When EMG is not feasible, muscle MRI and ultrasound can give an indirect view of muscle health, and clinical follow-up over time remains a legitimate strategy. When genetic testing is declined or inconclusive, muscle biopsy, a minor surgical procedure that removes a small piece of muscle for microscopic study, can identify missing or abnormal proteins directly. Nerve biopsy is used far less often, reserved for specific situations where other tests have failed to explain a neuropathy.

Choosing among these paths depends on the individual case, and the decision sits with the treating team in discussion with the patient.

What people often get wrong about EMG, nerve studies and genetic tests

The first misunderstanding is that a normal EMG means nothing is wrong. Electrodiagnostic testing samples large, fast nerve fibers and selected muscles at one moment in time. Small-fiber neuropathies, which affect pain and temperature nerves, produce entirely normal nerve conduction studies. Early nerve injury can be silent for weeks. Some muscle diseases fluctuate. A normal study narrows the field and is genuinely reassuring in many situations, but it does not close the case if symptoms persist, and a good neurologist will say so.

The second is the reverse: that an abnormal EMG is a diagnosis. It is a pattern. The same electrical picture of muscle disease can come from an inherited dystrophy, an autoimmune myositis, a thyroid problem or a medicine side effect. The report is a map that says where to look, not a label.

Third, people assume genetic testing is a yes-or-no result. In practice, a meaningful share of results fall into the uncertain category, and a negative panel does not exclude an inherited cause; it excludes the genes that were read, in the way they were read. Laboratories reclassify variants as evidence accumulates, and it is reasonable to ask whether reanalysis is planned.

Fourth, the phrase degenerative neurological and neuromuscular disease is often heard as a single sentence of doom. Degenerative simply means that cells are being lost over time rather than damaged by a one-off event. The pace ranges enormously across conditions and across people with the same condition, and many are now managed actively for decades.

Fifth, a family history is not required. Many inherited neuromuscular conditions arise from a new variant in the affected person, or are recessive, meaning both parents were unaffected carriers. Absence of a family story does not rule genetics out, and presence of one does not rule other causes in.

How are neuromuscular diseases treated once the tests point to a cause?

The honest framing is that the diagnosis changes the plan more than it changes the tools. Most neuromuscular conditions are managed by a team rather than a single prescription, and the team is assembled according to which tissue is affected and which organs are at risk.

For acquired conditions identified along the way, treatment targets the cause. An inflammatory neuropathy or myositis is treated by calming the immune system, using medicine classes chosen and monitored by the prescribing neurologist. A vitamin deficiency is replaced. A compressed nerve is relieved by activity changes, splinting or, in some cases, surgery. In these situations the electrodiagnostic study often serves a second purpose later, documenting whether nerves are recovering.

For inherited conditions, the approach is organized around function and surveillance. Physical and occupational therapy maintain range of motion and independence. Orthotic devices support weak joints. Because several dystrophies affect the heart muscle and the muscles of breathing, regular cardiac and respiratory monitoring becomes a fixed part of life, and knowing the precise genetic type tells the team how often to check and what to check for. The NHS and MedlinePlus both describe this multidisciplinary model as the standard of care for muscular dystrophy.

A small but growing number of inherited neuromuscular conditions now have disease-modifying treatments that act on the underlying genetic mechanism, for example by altering how a faulty gene is read or by supplying a working copy. Eligibility for these depends on the exact variant, which is one of the strongest practical reasons a precise genetic diagnosis matters. Whether any such option is appropriate, and how its benefits and risks weigh in an individual case, is a decision for the treating specialist, and it should never be inferred from a laboratory report alone.

Questions to ask your care team before and after the tests

A short list carried into the appointment often does more than an hour of searching afterwards. These are the questions neurologists say they wish more people asked.

• Which part of the pathway do you suspect is affected, nerve, junction or muscle, and what in my examination makes you think so?
• Is this the right time for EMG, or would waiting a few weeks make the study more informative?
• Will you test both sides, and which muscles do you plan to sample?
• Are there medicines or supplements I take that could affect the nerve study, the CK result or the interpretation?
• If the electrical study points to muscle, what blood tests and imaging will you use to distinguish an inherited from an acquired cause?
• Which genetic test are you recommending, a single gene, a panel or exome sequencing, and why that one?
• Does this test look for repeat expansions and deletions as well as sequence changes?
• Roughly how long until results are back, and who will explain them to me?
• What happens if a variant of uncertain significance is found, and is reanalysis planned later?
• If the result is positive, who else in my family might want to consider testing, and can a genetic counselor speak with them?
• If everything comes back normal but symptoms continue, what would the next step be?
• Which specialists, such as cardiology, pulmonology or physical therapy, should be part of my care depending on the result?

Answers to these do not require special vocabulary, and asking them signals to the team that the person in the chair wants to be a partner in the process. Bring a notebook, or a family member who can listen while the patient asks.

When to call your doctor: red-flag signs during the diagnostic process

Most of the neuromuscular work-up moves at a deliberate pace, and that is appropriate for slowly progressive conditions. Certain changes, however, should not wait for the next scheduled appointment.

Seek urgent care, or call emergency services, for any difficulty breathing, shortness of breath when lying flat, a weak cough, or trouble swallowing that causes choking or food going the wrong way. The muscles of breathing and swallowing can be affected by several neuromuscular conditions, and weakness there is a medical emergency regardless of the stage of testing.

Call the treating team the same day for weakness that spreads noticeably over hours or days rather than months, new double vision or drooping eyelids, loss of bladder or bowel control, sudden severe back pain with leg weakness, or dark, cola-colored urine after exertion, which can signal rapid muscle breakdown.

After the EMG itself, contact the laboratory or referring doctor if a needle site becomes increasingly red, hot and swollen, if there is persistent bleeding, or if pain in a muscle worsens after the first two days instead of easing. These complications are uncommon, but they are straightforward to address when reported early.

During the wait for genetic results, reach out sooner rather than later if anxiety is interfering with sleep, work or relationships. Genetic counselors and neurology nurses expect these calls, and support during the waiting period is part of the service, not an imposition.

Finally, if a diagnosis has been given and a new symptom appears in a part of the body not previously affected, such as palpitations, fainting, or morning headaches that may point to overnight breathing problems, report it. A precise diagnosis is valuable precisely because it tells the team which of these signs matter most for a particular condition, and every decision about what to do next belongs to that team.

Frequently asked questions

What is the most common neuromuscular disease?

It depends on how the category is drawn. Acquired peripheral neuropathy, most often related to diabetes, is by far the most common condition affecting peripheral nerves. Among inherited disorders, Charcot-Marie-Tooth disease is one of the most common inherited neurological conditions, and Duchenne muscular dystrophy is the most common muscular dystrophy diagnosed in children. Your neurologist will consider common causes before rare ones.

What is degenerative neurological and neuromuscular disease?

Degenerative means nerve or muscle cells are being lost gradually over time, rather than damaged by a single event such as injury or infection. The term covers a wide range of conditions with very different speeds and outlooks, from slowly progressive inherited neuropathies to motor neuron diseases. The label describes a process, not a specific prognosis, and only a complete evaluation can say which condition applies.

Nerve conduction study vs EMG: do I need both?

Usually yes, because they answer different questions. The nerve conduction study evaluates peripheral nerves and the neuromuscular junction from the skin surface. Needle EMG samples the muscle itself and can reach deep muscles supplied by nerve roots near the spine. Together they locate the problem far more precisely than either alone. Your neurologist may occasionally order only one when the clinical question is narrow.

What does an EMG show that blood tests cannot?

An EMG shows the electrical behavior of muscle and its nerve supply in real time, including whether the problem lies in nerve or muscle, how active it is, and how it is distributed across the body. Blood tests such as creatine kinase can suggest that muscle is breaking down but cannot say where or why. The two are complementary, and neither replaces the physical examination.

How accurate is genetic testing for muscular dystrophy?

When a specific type is strongly suspected and the right test is chosen, genetic testing frequently confirms the diagnosis and identifies the exact variant. It is not infallible. Some variants fall into an uncertain category, and standard sequencing can miss repeat expansions or large deletions unless those are tested separately. A negative result with a convincing clinical picture may lead to broader sequencing or muscle biopsy.

Does the EMG hurt, and can I drive home afterwards?

The nerve stimulation feels like brief static shocks, and the needle insertion feels like a series of quick pinches, more noticeable in small muscles. Most people find it uncomfortable rather than severely painful. No sedation is used, so driving home is normally fine, and Mayo Clinic notes that usual activities can resume immediately. Tell the examiner if pain is significant so the plan can be adjusted.

How do you treat neuromuscular diseases once they are diagnosed?

Treatment depends entirely on the cause. Acquired conditions such as inflammatory neuropathies, vitamin deficiencies or compressed nerves are treated by addressing that cause. Inherited conditions are managed by a team using physical therapy, orthotic support and regular monitoring of the heart and breathing muscles. A growing number of inherited conditions have treatments aimed at the genetic mechanism, and eligibility depends on the exact variant, which the prescribing specialist will assess.

What are the symptoms of neuromuscular pain, and when should I see a doctor?

Pain from nerve or muscle disease varies widely: burning, tingling or electric sensations tend to suggest nerve involvement, while deep aching, cramping or tenderness after minimal activity can suggest muscle. Pain alone rarely identifies a cause. See a doctor if pain comes with weakness, wasting, falls, trouble with stairs or buttons, or a family history of similar problems; seek urgent care for breathing or swallowing difficulty.

How long do genetic test results take?

MedlinePlus notes that results can take from a few days to several weeks depending on the type of test, and broad analyses such as exome sequencing commonly take longer than single-gene tests. The laboratory and your care team can give a typical range for the specific test ordered. Scheduling a results appointment with a genetic counselor or neurologist at the time of sampling reduces uncertainty.

Can a neuromuscular disease be inherited if nobody in my family has it?

Yes. Many inherited neuromuscular conditions arise from a new variant that appeared for the first time in the affected person. Others are recessive, meaning both parents carry one copy without symptoms. Some conditions are mild or late-onset in relatives who were never diagnosed. A lack of family history therefore does not rule out a genetic cause, which is why testing is guided by the clinical picture rather than pedigree alone.

References

• MedlinePlus: Electromyography (EMG) and Nerve Conduction Studies
• MedlinePlus Genetics: Genetic Testing
• NHS: Muscular dystrophy – Diagnosis
• MedlinePlus: Muscular Dystrophy

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.